Lantern Pharma (NASDAQ:LTRN) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Lantern Pharma (NASDAQ:LTRN) from a hold rating to a sell rating in a report published on Saturday.

Separately, Weiss Ratings upgraded shares of Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Lantern Pharma Stock Up 0.8%

NASDAQ:LTRN opened at $2.65 on Friday. Lantern Pharma has a twelve month low of $1.11 and a twelve month high of $4.75. The stock’s 50-day simple moving average is $3.31 and its 200 day simple moving average is $2.85. The firm has a market capitalization of $33.81 million, a PE ratio of -1.64 and a beta of 2.34.

Lantern Pharma (NASDAQ:LTRN) last issued its earnings results on Friday, August 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.19).

Institutional Trading of Lantern Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Empery Asset Management LP bought a new position in Lantern Pharma in the 2nd quarter valued at approximately $3,513,930,000. Vanguard Group Inc. increased its position in Lantern Pharma by 5.6% in the 3rd quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock valued at $1,671,000 after acquiring an additional 20,321 shares during the period. Renaissance Technologies LLC increased its position in Lantern Pharma by 5.1% in the 1st quarter. Renaissance Technologies LLC now owns 116,000 shares of the company’s stock valued at $159,000 after acquiring an additional 5,600 shares during the period. Geode Capital Management LLC raised its stake in shares of Lantern Pharma by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock valued at $293,000 after acquiring an additional 4,661 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new position in shares of Lantern Pharma during the third quarter valued at $170,000. 28.62% of the stock is currently owned by institutional investors.

Lantern Pharma Company Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.